Pruritus

Nov 1, 2025 by in ONCOLOGY Comments Off on Pruritus

Pruritus David Croitoru Ehsan Azimi Maxwell B. Sauder The experience of pruritus among cancer patients is common, frequently leads to decreased quality of life, and may be related to multiple…

read more

Radiation Therapy

Nov 1, 2025 by in ONCOLOGY Comments Off on Radiation Therapy

Radiation Therapy Beth McLellan ACUTE RADIATION DERMATITIS Acute radiation dermatitis (RD) occurs within 90 days after radiation therapy (RT). It is most common among patients with breast, head and neck,…

read more

Thalidomide and Lenalidomide

Nov 1, 2025 by in ONCOLOGY Comments Off on Thalidomide and Lenalidomide

Thalidomide and Lenalidomide Pearl O. H. Ugwu-Dike Yevgeniy Semenov Thalidomide and lenalidomide are antiangiogenic, antineoplastic, immunomodulatory agents used in the management of a wide range of conditions. Thalidomide, historically used…

read more

Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors

Nov 1, 2025 by in ONCOLOGY Comments Off on Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors

Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Michael S. Chang Rebecca I. Hartman Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) functions as an immune checkpoint in negatively regulating T-cell function. T-cell activation requires…

read more

CCR4 Inhibitors

Nov 1, 2025 by in ONCOLOGY Comments Off on CCR4 Inhibitors

CCR4 Inhibitors Cesar Antonio Virgen Cecelia Alejandra Larocca Mogamulizumab is the only FDA-approved C-C chemokine receptor type 4 (CCR4) inhibitor. It is approved for the treatment of relapsed or refractory…

read more

Hormonal Therapies

Nov 1, 2025 by in ONCOLOGY Comments Off on Hormonal Therapies

Hormonal Therapies Jane J. Han Lauren M. Guggina Hormones, such as estrogen and androgens, are important in the initiation and proliferation of endocrine-sensitive cancers. Therefore, hormonal therapy is commonly used…

read more

Proteasome Inhibitors

Nov 1, 2025 by in ONCOLOGY Comments Off on Proteasome Inhibitors

Proteasome Inhibitors Abdulhadi Jfri Victor Huang Ian W. Tattersall Proteasome inhibitors are a group of agents that inhibit the ubiquitin proteasome pathway, which regulates multiple cellular processes, including cell growth…

read more

Fibroblast Growth Factor Receptor (FGFR) Inhibitors

Nov 1, 2025 by in ONCOLOGY Comments Off on Fibroblast Growth Factor Receptor (FGFR) Inhibitors

Fibroblast Growth Factor Receptor (FGFR) Inhibitors Catherine Pisano Christopher Iriarte Nicole R. LeBoeuf Fibroblast growth factors (FGFs) and their receptors (FGFRs) play an important role in normal cell biology, including…

read more

BCR/ABL/C-Kit Inhibitors

Nov 1, 2025 by in ONCOLOGY Comments Off on BCR/ABL/C-Kit Inhibitors

BCR/ABL/C-Kit Inhibitors Catherina X. Pan Vinod E. Nambudiri The B-cell receptor (BCR) pathway is a complex signaling cascade involved in B-cell activation, whose aberrant activation leads to leukemias and lymphomas.1…

read more
Get Clinical Tree app for offline access